Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Contrast Agents' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Contrast Agents' found in 17 terms [] and 118 definitions []
previous     86 - 90 (of 135)     next
Result Pages : [1 2 3 4]  [5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... ]
Searchterm 'Contrast Agents' was also found in the following services: 
spacer
News  (49)  Resources  (7)  Forum  (8)  
 
GadodiamideInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Gd-DTPA-BMA, generic name: Gadodiamide, chemical compound: Gd-diethylenetriaminepentaacetate-bis(methylamide), central moiety: Gd
A paramagnetic MRI contrast agent (nonionic) with a small molecular weight linear chelate. Due to the linkage of two DTPA molecules through amide bonds the molecule is uncharged and has a low osmolality. The substance is excreted almost exclusively by the kidneys.

See also Nonionic Intravenous Contrast Agents and Omniscan®.
spacer
Searchterm 'Contrast Agents' was also found in the following services: 
spacer
Radiology  (46) Open this link in a new windowUltrasound  (75) Open this link in a new window
Gadolinium ZeoliteInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
(Gadolite® oral Suspension) An oral paramagnetic MRI contrast agent to enhance delineation of the bowel. Zeolites are hydrated aluminosilicates with large holes that can provide a temporary home for guest molecules like gadolinium. Zeolites modified with Gd (III) are effective positive MRI contrast agents for gastrointestinal application.
spacer

• View the DATABASE results for 'Gadolinium Zeolite' (3).Open this link in a new window

MRI Resources 
Coils - Shoulder MRI - Education - Services and Supplies - Used and Refurbished MRI Equipment - Cochlear Implant
 
Gadomer 17InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: (Gd-DTPA)-17, 24 cascade polymer, generic name: Gadomer-17, 24, central moiety: Gd2+, relaxivity: r1=11.9, B0=1.0 T, r2=16.5, Dose: 0.05 mmol/kg
An intravascular macromolecular MRI contrast agent with positive enhancement under development (Bayer Schering Pharma AG) for MR angiography and tumor differentiation. The synthetic dendrimer with large molecular weight (17kD - limits agent to vascular space) is linked to Gadolinium. The renal excretion is slowed to intermediate molecular size. In MRA a longer lasting venous and arterial enhancement was seen with Gadomer-17 due to the particular pharmacokinetics of this agent.

See also Tumor Specific Agents, and Intravascular Contrast Agents.
spacer

• View the DATABASE results for 'Gadomer 17' (3).Open this link in a new window


• View the NEWS results for 'Gadomer 17' (1).Open this link in a new window.
 
Further Reading:
  News & More:
Combined MR lymphangiography and MR imaging-guided needle localization of sentinel lymph nodes using Gadomer-17.
2002
Searchterm 'Contrast Agents' was also found in the following services: 
spacer
News  (49)  Resources  (7)  Forum  (8)  
 
Gadopentetate DimeglumineInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: Gd-DTPA, generic name: Gadopentetate dimeglumine, chemical compound: Gadolinium-diethylenetriaminepentaacetic acid
Gadopentetate dimeglumine was introduced in 1981, as the first paramagnetic MRI contrast agent (ionic). The Gd-induced dipole dipole interactions lead to shortening of T1, which results in contrast enhancement on T1 weighted images. The used metal ion Gd3+ (gadolinium) is toxic, and therefore bound in the renally excreted DTPA chelate, a very stable complex. The Gd-complex also induce susceptibility effects, as a result of the magnetic field gradient between the contrast agent in the blood vessels and the surrounding tissue, that lead to shortening of T2 or T2*.
Following intravenous administration, the compound is distributed rapidly in the extracellular space and is eliminated unchanged by glomerular filtration via the kidneys. Up to 6 hours, post injection an average of 83% of the dose is eliminated renal.

See also Magnevist®, Gadolinium and Contrast Agents.
spacer

• View the DATABASE results for 'Gadopentetate Dimeglumine' (5).Open this link in a new window

 
Further Reading:
  Basics:
Magnevist Package Insert
2000
Gadopentetic acid
   by en.wikipedia.org    
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
Searchterm 'Contrast Agents' was also found in the following services: 
spacer
Radiology  (46) Open this link in a new windowUltrasound  (75) Open this link in a new window
Gadopentetate GastrointestinalInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Gd-DTPA (Magnevist® Enteral) for gastrointestinal use with 1 mmolar required concentration.

See also Positive Oral Contrast Agents.
spacer

• View the DATABASE results for 'Gadopentetate Gastrointestinal' (3).Open this link in a new window

MRI Resources 
Diffusion Weighted Imaging - Most Wanted - DICOM - Process Analysis - Journals - Pregnancy
 
previous      86 - 90 (of 135)     next
Result Pages : [1 2 3 4]  [5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... ]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



MRI is trending to low field magnets :
reduced costs will lead to this change 
AI will close the gap to high field 
only in remote areas 
is only temporary 
never 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]